H. Sandler

发表

Prostate position late in the course of external beam therapy: patterns and predictors.

R. Zellars, P. Roberson, M. Strawderman, 2000, International journal of radiation oncology, biology, physics.

Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.

J. Pouliot, I. Hsu, H. Sandler, 2008, International journal of radiation oncology, biology, physics.

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.

John T. Wei, R. Dunn, J. Montie, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.

John T. Wei, David C. Miller, R. Dunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer.

John T. Wei, J. Pouliot, J. Balter, 2006, International journal of radiation oncology, biology, physics.

Influence of intrafraction motion on margins for prostate radiotherapy.

Patrick A Kupelian, James M Balter, Twyla R Willoughby, 2006, International journal of radiation oncology, biology, physics.

A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors.

D L McShan, R K Ten Haken, D J Quint, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy.

H. Sandler, M. Kessler, D. McShan, 1999, Seminars in radiation oncology.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

P. Kantoff, L. Collette, M. Sydes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

A. Markoe, K. Russell, H. Sandler, 2000, International journal of radiation oncology, biology, physics.

Quality of life and satisfaction with outcome among prostate-cancer survivors.

John T. Wei, D. Kuban, I. Kaplan, 2008, The New England journal of medicine.

Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy

H. Sandler, D. Hamstra, C. Pan, 2012, Radiation Oncology.

Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.

Richard Tuli, Yong Yue, H. Sandler, 2017, Journal of gastrointestinal oncology.

Adequacy of inhale/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT

Benedick A Fraass, Richard Tuli, Wensha Yang, 2014, Radiation oncology.

Measurement of prostate movement over the course of routine radiotherapy using implanted markers.

K Lam, J M Balter, R K ten Haken, 1995, International journal of radiation oncology, biology, physics.

Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.

Issam El-Naqa, Mack Roach, Charles Catton, 2007, International journal of radiation oncology, biology, physics.

The Clinical Utility of Magnetic Resonance Imaging in 3-Dimensional Treatment Planning of Brain Neoplasms

H. Sandler, D. McShan, B. Fraass, 1993 .

Four-Dimensional Magnetic Resonance Imaging With 3-Dimensional Radial Sampling and Self-Gating-Based K-Space Sorting: Early Clinical Experience on Pancreatic Cancer Patients.

Benedick A Fraass, Debiao Li, Jianing Pang, 2015, International journal of radiation oncology, biology, physics.

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Adam P Dicker, Charles R. Thomas, I-Chow Hsu, 2018, The Lancet. Oncology.

Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215.

H. Sandler, J. Speight, T. Pisansky, 2011, The journal of sexual medicine.

Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.

H. Sandler, K. Bae, J. Efstathiou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer

K. Pienta, H. Sandler, Asmita R Patel, 2005 .

The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D

Lawrence D. True, Beatrice S. Knudsen, Mark A. Rubin, 2014, Archives of pathology & laboratory medicine.

The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma.

Mohammed U Kabeto, David C. Smith, H. Sandler, 2002, International Journal of Radiation Oncology, Biology, Physics.

A comparison of ventilatory prostate movement in four treatment positions.

J M Balter, H M Sandler, D W Litzenberg, 2000, International journal of radiation oncology, biology, physics.

The effect of patient position and treatment technique in conformal treatment of prostate cancer.

R K Ten Haken, H M Sandler, P. Roberson, 1999, International journal of radiation oncology, biology, physics.

Nonlocal Means Denoising of Self-Gated and k-Space Sorted 4-Dimensional Magnetic Resonance Imaging Using Block-Matching and 3-Dimensional Filtering: Implications for Pancreatic Tumor Registration and Segmentation.

H. Sandler, K. Sheng, Debiao Li, 2016, International journal of radiation oncology, biology, physics.

A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.

H. Sandler, K. Bae, M. Kuettel, 2006, Brachytherapy.

Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone.

W. Curran, H. Sandler, W. Mckenna, 1992, International journal of radiation oncology, biology, physics.

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

D. Beyer, C. Catton, H. Sandler, 2017, International journal of radiation oncology, biology, physics.

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

A. Markoe, J. Earle, H. Sandler, 2002, International journal of radiation oncology, biology, physics.

Evaluating the relationships between rectal normal tissue complication probability and the portion of seminal vesicles included in the clinical target volume in intensity-modulated radiotherapy for prostate cancer.

H. Sandler, R. T. Ten Haken, K. Vineberg, 2009, International journal of radiation oncology, biology, physics.

3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients

H. Sandler, P. McLaughlin, J. Forman, 1993 .

Determinants of change in prostate-specic antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in

L. Kestin, H. Sandler, K. Bae, 2008 .

Number of Unfavorable Intermediate‐Risk Factors Predicts Pathologic Upstaging and Prostate Cancer‐Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database

M. Terris, M. Cooperberg, H. Sandler, 2017, The Prostate.

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy.

R. Dunn, H. Sandler, P. McLaughlin, 2000, International journal of radiation oncology, biology, physics.

Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis.

M. Luu, H. Sandler, Z. Zumsteg, 2021, Urologic oncology.

"Examinations in Radiation Oncology: Listening, Learning, and Looking Forward Together".

L. Wilson, H. Sandler, T. DeWeese, 2019, International journal of radiation oncology, biology, physics.

3-D Conformal Radiotherapy for Brain Tumors

H. Sandler, 1996 .

3-D conformal radiotherapy for brain tumors. The University of Michigan experience.

H. Sandler, 1996, Frontiers of radiation therapy and oncology.

Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.

H. Sandler, K. Bae, D. Taussky, 2008, Urology.

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients

M. Rubin, R. Kuefer, M. Loeffler, 2004, Prostate Cancer and Prostatic Diseases.

Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.

H. Sandler, F. Feng, M. Sanda, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of a prospective multi-institutional phase II trial (RTOG 98–05) of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate

W. R. Lee, D. Grignon, H. Sandler, 2004 .

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Anne E. Calvaresi, P. Carroll, A. M. López, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

D. Low, H. Sandler, G. Rodrigues, 2022, The Lancet.

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014.

K. Pienta, H. Sandler, 2003, Reviews in urology.

The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.

H. Sandler, P. McLaughlin, C. Pan, 2003, International journal of radiation oncology, biology, physics.

Combined modality treatment for prostate cancer: role of chemotherapy.

David C. Smith, H. Sandler, S. Narayan, 2003, Seminars in oncology.

The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer.

W. Curran, H. Sandler, A. Turrisi, 1990, International journal of radiation oncology, biology, physics.

Reply to S.G. Williams et al

H. Sandler, K. Bae, L. Souhami, 2009 .

Single‐fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient

M. Suntharalingam, H. Sandler, L. Kachnic, 2013, Cancer.

The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.

H. Sandler, F. Feng, D. Hamstra, 2011, International journal of radiation oncology, biology, physics.

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

M. Kattan, H. Sandler, P. McLaughlin, 2006, The Journal of urology.

Hormone therapy and radiotherapy for intermediate risk prostate cancer.

H. Sandler, Irwin H. Lee, 2008, Seminars in radiation oncology.

NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network.

P. Kantoff, P. Walsh, P. Lange, 1996, Oncology.

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.

A. Kishan, R. Mehra, H. Sandler, 2021, The Lancet. Oncology.

Predicting biochemical failure and overall survival through intratherapy PSA changes during definitive external beam radiotherapy.

Jeremy MG Taylor, R. Andridge, H. Sandler, 2008, International journal of radiation oncology, biology, physics.

Chemotherapy for localized, high-risk prostate cancer.

David C. Smith, H. Sandler, S. Narayan, 2003, Seminars in radiation oncology.

Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02

H. Sandler, M. Desilvio, W. Shipley, 2003 .

Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial

J. Galvin, H. Sandler, J. Bahary, 2013 .

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, S. Yeung, 2022, npj Digital Medicine.

Active surveillance for prostate cancer: the role of the pathologist.

M. Rubin, A. Chinnaiyan, B. Delahunt, 2015, Pathology.

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Christopher U. Jones, K. Pienta, H. Sandler, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Overview of bladder cancer trials in the Radiation Therapy Oncology Group

H. Sandler, W. Shipley, W. Tester, 2003, Cancer.

Metastatic epidural spinal cord compression: current concepts and treatment

H. Sandler, S. Papadopoulos, H. Greenberg, 2005, Journal of Neuro-Oncology.

Spinal Cord AstrocytomasResults of Therapy

D. Ross, H. Sandler, A. Thornton, 1992 .

Spinal cord astrocytomas: results of therapy.

D. Ross, H. Sandler, A. Thornton, 1992, Neurosurgery.

Stereotactic Radiosurgery of a Patient with Severe Kyphosis

D. Ross, J. Balter, H. Sandler, 1998 .

Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology.

R. Komaki, H. Sandler, L. Gaspar, 2014, Practical radiation oncology.

Discriminating lung adenocarcinoma from lung squamous cell carcinoma using respiration-induced tumor shape changes

N. Lepore, H. Sandler, R. Tuli, 2018, Physics in medicine and biology.

NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer

D. Low, H. Sandler, M. Amin, 2016 .

VA-Radiation Oncology Quality Surveillance Program.

L. Potters, I. Chetty, J. DeMarco, 2020, International journal of radiation oncology, biology, physics.

Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5.

H. Sandler, P. McLaughlin, F. Feng, 2011, Brachytherapy.

Do not count out external-beam radiation therapy for high-risk prostate cancer.

H. Sandler, J. Michalski, D. Hamstra, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant postoperative radiotherapy following radical prostatectomy: is now the time?

H. Sandler, 2006, Nature Clinical Practice Oncology.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2016, European urology.

Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complications of prostate cancer treatment.

Ronald C. Chen, A. Zietman, H. Sandler, 2014, The Lancet. Oncology.

Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.

R. Mehra, H. Sandler, W. Jackson, 2013, International journal of radiation oncology, biology, physics.

Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.

H. Sandler, M. Eisenberger, 2007, The Journal of urology.

3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review.

H. Sandler, P. McLaughlin, É. Vigneault, 2000, International journal of radiation oncology, biology, physics.

CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective.

H. Sandler, K. Oh, 2008, Urology.

In response to Dr. Yan et al.

K. Lam, J. Balter, H. Sandler, 2006 .

WE-D-I-6B-09: Tracking Prostate Motion and Isocenter Offset During Treatment Using the Calypos(tm) 4D Localization System

H. Sandler, P. Kupelian, T. Willoughby, 2005 .

Dose escalation for prostate cancer: which dose for which person?

H. Sandler, 2002, Frontiers of radiation therapy and oncology.

NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.

D. Dearnaley, M. Harisinghani, H. Sandler, 2020, International journal of radiation oncology, biology, physics.

Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer.

H. Sandler, P. McLaughlin, M. Schipper, 2008, Urology.

Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop.

P. Carroll, P. Scardino, I. Thompson, 2014, Urology.

Radiosensitization with carotid intra‐arterial bromodeoxyuridine ± 5‐fluorouracil biomodulation for malignant gliomas

H. Sandler, L. Junck, W. Ensminger, 1994, Neurology.

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

A. Zietman, H. Sandler, R. Dess, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitions of biochemical failure in prostate cancer following radiation therapy.

K. Griffith, H. Sandler, J. M. Taylor, 2001, International journal of radiation oncology, biology, physics.

Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment

H. Sandler, P. McLaughlin, W. Jackson, 2022, Clinical and translational radiation oncology.

Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.

David C. Smith, J. Montie, H. Sandler, 2009, International Journal of Radiation Oncology, Biology, Physics.

Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.

J. Oesterling, K. Cooney, E. Lange, 1998, Journal of the National Cancer Institute.

Can Electronic Web-Based Technology Improve Quality of Life Data Collection? Analysis of RTOG 0828

H. Sandler, W. Lee, D. Watkins-Bruner, 2014 .

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop.

P. Carroll, B. Freidlin, D. Song, 2019, The Journal of urology.

Cystic Cervical Intramedullary Ependymoma with Previous lntracyst Hemorrhage: Magnetic Resonance Imaging at 1.5 T

H. Sandler, J. Brunberg, P. Mckeever, 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

MDM2 as a predictor of prostate carcinoma outcome

D. Grignon, M. Hammond, H. Sandler, 2005, Cancer.

Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?

H. Sandler, P. Robertson, J. Goldwein, 1998, International journal of radiation oncology, biology, physics.

Invasive Bladder Cancer: Combined Modality Treatment

H. Sandler, D. Raghavan, 2015 .

Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy

H. Sandler, D. Raghavan, 2008 .

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial

D. Low, H. Sandler, G. Swanson, 2019, JAMA oncology.

High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis

H. Sandler, M. Kamrava, E. Anderson, 2021, Journal of contemporary brachytherapy.

2 Patterns of failure following 3-D conformal dose escalation radiotherapy for high grade astrocytomas — A quantitative dosimetric study

M. Martel, H. Sandler, S. Gebarski, 1996 .

No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.

H. Sandler, S. Daignault, M. Ray, 2009, Urology.

Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States.

P. Warde, H. Sandler, G. Deboer, 2002, The Canadian journal of urology.

The evolution of chemotherapy for the treatment of prostate cancer.

J. Eastham, H. Sandler, L. Horvath, 2017 .

Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

A. Zietman, H. Sandler, W. Shipley, 2005, Seminars in radiation oncology.

Preliminary patient‐reported outcomes analysis of 3‐dimensional radiation therapy versus intensity‐modulated radiation therapy on the high‐dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial

J. Galvin, H. Sandler, M. Amin, 2015, Cancer.

Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406

A. Markoe, H. Sandler, J. Purdy, 2000 .

A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

M. Michaelson, H. Sandler, G. Swanson, 2017, International journal of radiation oncology, biology, physics.

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (Trial ****)

M. Michaelson, H. Sandler, G. Swanson, 2017 .

Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia.

P. Warde, H. Sandler, R. Choo, 2002, Australasian radiology.

Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.

David C. Smith, K. Griffith, J. Montie, 2004, Urology.

Organ preservation in muscle-invasive bladder cancer.

H. Sandler, Shaneli A Fernando, 2005, Oncology.

The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy – Authors’ reply

H. Sandler, A. Pollack, O. Sartor, 2022, The Lancet.

Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).

Christopher U. Jones, A. Kishan, M. Sydes, 2022, European urology.

Predicting Biochemical Failure and Overall Survival Through Intra-therapy PSA Changes During Definitive External Beam Radiation

Jeremy MG Taylor, R. Andridge, H. Sandler, 2018 .

Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer.

Jeremy MG Taylor, R. Andridge, H. Sandler, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

163 Evaluation of a clinical megavoltage imager based on active matrix, flat-panel technology

V. Scarpine, H. Sandler, J. Siewerdsen, 1996 .

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial RTOG 0415

J. Deasy, D. Low, H. Sandler, 2019 .

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis

A. Kishan, L. Collette, T. D. de Reijke, 2019, JAMA oncology.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

John T. Wei, H. Sandler, R. Dess, 2018, Practical radiation oncology.

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Jonathan E. Shoag, A. Kishan, M. Sydes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Overall Treatment Time in the Management of Prostate Cancer Patients: How to Manage Unscheduled Treatment Interruptions.

H. Sandler, 2018, International journal of radiation oncology, biology, physics.

3-D conformal radiotherapy for prostate cancer. The University of Michigan experience.

H. Sandler, 1996, Frontiers of radiation therapy and oncology.

Localization of the prostatic apex for radiation therapy using implanted markers.

H M Sandler, A S Lichter, H. Grossman, 1993, International journal of radiation oncology, biology, physics.

Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.

H. Sandler, F. Feng, D. Hamstra, 2011, International journal of radiation oncology, biology, physics.

Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

A. Zietman, H. Sandler, R. Dess, 2019, International Journal of Radiation Oncology*Biology*Physics.

Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV

A. Markoe, H. Sandler, J. Purdy, 2002 .

Analysis of the possibility that transurethral resection promotes metastasis in prostate cancer

H. Sandler, G. Hanks, Gerald E. Hanks, 1988, Cancer.

Stereotactic body radiation therapy: Let's not give up on progress.

H. Sandler, James B. Yu, 2015, Practical radiation oncology.

Evaluation of nuclear factor κB and chemokine receptor CXCR4 co‐expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

H. Sandler, Liang Cheng, A. Dicker, 2011, BJU international.

Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.

David C. Smith, J. Montie, H. Sandler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Jeremy MG Taylor, L. Kestin, H. Sandler, 2007, International journal of radiation oncology, biology, physics.

Multimodality bladder preservation therapy for muscle-invasive bladder tumors.

H. Sandler, Shaneli A Fernando, 2007, Seminars in oncology.

Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer.

K. Pienta, H. Sandler, Asmita R Patel, 2005, Clinical genitourinary cancer.

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

D. Grignon, A. Zietman, H. Sandler, 2016 .

Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003.

L. Potters, R. Hannan, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma

D. Beyer, C. Catton, H. Sandler, 2016 .

Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).

I. Kaplan, D. Beyer, H. Sandler, 2016 .

NCCN Practice Guidelines for Prostate Cancer.

P. Kantoff, P. Scardino, J. Pow-Sang, 2000, Oncology.

Drivers of Medicare Spending: A 15 Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared to Other Specialties.

H. Sandler, P. Johnstone, James B. Yu, 2021, International journal of radiation oncology, biology, physics.

The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis

D. Kuban, M. Zelefsky, A. Zietman, 2004 .

Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

D. Low, H. Sandler, É. Vigneault, 2018, International Journal of Radiation Oncology*Biology*Physics.

Reply to L. Collette et al and C.M. Tangen et al

H. Sandler, K. Bae, L. Souhami, 2009 .

Patterns of Practice in Radiation Dose Prescription and Treatment Planning for Patients With Lung Cancer Among Members of American Society of Therapeutic Radiology and Oncology

H. Choy, R. Komaki, H. Sandler, 2007 .

Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

J. McKenney, M. Kattan, P. Choyke, 2017, CA: a cancer journal for clinicians.

Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Issam El Naqa, Mark K Buyyounouski, Richard K Valicenti, 2010, International journal of radiation oncology, biology, physics.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Richard K Valicenti, Jeff M Michalski, Michael W Kattan, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL

D. Low, H. Sandler, J. Michalski, 2019, Journal of Urology.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.

K. Hoffman, H. Sandler, J. Efstathiou, 2018, Practical radiation oncology.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

K. Hoffman, H. Sandler, J. Efstathiou, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial

H. Sandler, M. Lock, J. Purdy, 2018, JAMA oncology.

Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.

Issam El Naqa, David Gaffney, Christopher Willett, 2012, International journal of radiation oncology, biology, physics.

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.

L. Kestin, H. Sandler, T. Pickles, 2011, International journal of radiation oncology, biology, physics.

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.

H M Sandler, M. Strawderman, H. Sandler, 1997, International journal of radiation oncology, biology, physics.

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management

H. Sandler, C. Bradford, S. Wong, 2007, Cancer.

Radiotherapy using a water bath in the treatment of Bowen's disease of the digit.

K. Griffith, H. Sandler, L. Pierce, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of radiotherapy for thyroid ophthalmopathy.

R. Sergott, H. Sandler, B. Fowble, 1989, International journal of radiation oncology, biology, physics.

Controversies in the management of stage I seminoma.

H. Sandler, J. Fiveash, 1998, Oncology.

Myxopapillary ependymoma results of nucleolar organizing region staining

D. Ross, H. Sandler, K. Muraszko, 1993, Cancer.

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

M. Prados, T. Cascino, W. Curran, 2004, International journal of radiation oncology, biology, physics.

The evolution of chemotherapy for the treatment of prostate cancer

J. Eastham, H. Sandler, L. Horvath, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prostate cancer. Clinical practice guidelines in oncology.

Anthony D'Amico, James Mohler, Alan Pollack, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Radiation Therapy for Clinically Localized Prostate Cancer

D. Kuban, S. Hancock, A. Zietman, 2016 .

The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse.

H. Sandler, F. Feng, M. Schipper, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Treatment strategies for high-risk locally advanced prostate cancer

H. Sandler, S. Rosenthal, 2010, Nature Reviews Urology.

Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.

R. Shah, H. Sandler, C. Pan, 2007, Urology.

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

D. Kuban, S. Hancock, A. Zietman, 1999, JAMA.

Obesity and mortality in men with locally advanced prostate cancer

H. Sandler, K. Bae, J. Efstathiou, 2007, Cancer.

A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2)

P. Lin, J. Moul, H. Sandler, 2020, Clinical Cancer Research.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options

Ronald C. Chen, Kirsten L. Greene, J. Cadeddu, 2018, The Journal of urology.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options

Ronald C. Chen, Kirsten L. Greene, J. Cadeddu, 2017, The Journal of urology.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy

Menggang Yu, Arul M. Chinnaiyan, Felix Y. Feng, 2017, JAMA oncology.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of the H-ras oncogene in radiation resistance and metastasis.

C. Ling, H. Sandler, B. Endlich, 1990, International journal of radiation oncology, biology, physics.

Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials.

H. Sandler, F. Feng, D. Spratt, 2022, International journal of radiation oncology, biology, physics.

Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.

J. Oesterling, K. Cooney, E. Lange, 1997, Journal of the National Cancer Institute.

Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs.

H. Tseng, R. Pei, T. Daskivich, 2023, Nano today.

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

H. Sandler, P. Tran, F. Feng, 2021, JAMA oncology.

Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?

F. Saad, H. Sandler, M. Carducci, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

W. R. Lee, A. Kishan, A. Zietman, 2020, JAMA oncology.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

R. Hannan, H. Sandler, J. Purdy, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

D. Grignon, A. Zietman, H. Sandler, 2017, The New England journal of medicine.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

D. Kuban, M. Zelefsky, A. Zietman, 2005, The Journal of urology.

Outcomes of multidisciplinary management in pediatric low-grade gliomas.

H. Sandler, P. Robertson, K. Muraszko, 2008, International journal of radiation oncology, biology, physics.

Radical radiotherapy for prostate cancer is the 'only way to go'.

H. Sandler, A. Mirhadi, 2009, Oncology.

Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.

John T. Wei, R. Shah, H. Sandler, 2007, International journal of radiation oncology, biology, physics.

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

D. Grignon, M. Hammond, H. Sandler, 2007, The Lancet. Oncology.

Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study.

M. Martel, H. Sandler, S. Gebarski, 1999, International journal of radiation oncology, biology, physics.

Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.

H. Sandler, P. McLaughlin, M. Strawderman, 1997, International journal of radiation oncology, biology, physics.

Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients.

H. Sandler, R. T. Ten Haken, P. McLaughlin, 1995, International journal of radiation oncology, biology, physics.

Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.

Min Zhang, H. Sandler, Yoshiyuki Suzuki, 2005, International journal of radiation oncology, biology, physics.

Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.

R. Jove, J. Torres-Roca, H. Sandler, 2007, Urology.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

S. Piantadosi, H. Sandler, S. Lo, 2019, EBioMedicine.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

M. Terris, A. Kishan, M. Cooperberg, 2019, JAMA oncology.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

M. Cooperberg, H. Sandler, P. Tran, 2018, European urology.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

P. Kantoff, M. Cooperberg, T. Rebbeck, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Paul Schellhammer, P. Schellhammer, H. Sandler, 2006, International journal of radiation oncology, biology, physics.

Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer.

H. Sandler, 2019, International Journal of Radiation Oncology, Biology, Physics.

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Christopher U. Jones, K. Pienta, D. Grignon, 2015, International journal of radiation oncology, biology, physics.

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analy

K. Pienta, H. Sandler, J. Michalski, 2009, International journal of radiation oncology, biology, physics.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients.

H. Sandler, M. N. Passarelli, S. Daignault, 2012, International journal of radiation oncology, biology, physics.

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

A. Kishan, T. D. de Reijke, H. Sandler, 2022, The Lancet. Oncology.

Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

I. Hsu, H. Sandler, M. Roach, 2013, Cancer.

Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.

H. Sandler, K. Bae, L. Souhami, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

D. Grignon, T. Pajak, H. Sandler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy.

J. DeMarco, H. Sandler, M. Kamrava, 2019, Brachytherapy.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

H. Sandler, M. Amin, T. Pisansky, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist

M. Rubin, A. Chinnaiyan, B. Delahunt, 2014, Virchows Archiv.

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

H. Sandler, F. Feng, D. Hamstra, 2011, International journal of radiation oncology, biology, physics.

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Christopher U. Jones, H. Sandler, M. Amin, 2011, The New England journal of medicine.

Surrogate end points for prostate cancer: what is prostate-specific antigen telling us?

H. Sandler, M. Desilvio, 2003, Journal of the National Cancer Institute.

Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses.

M. Martel, H. Sandler, W. Roa, 1994, International journal of radiation oncology, biology, physics.

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.

H. Sandler, R. Valicenti, S. Rosenthal, 2017, International journal of radiation oncology, biology, physics.

11: Impact of Prostate Cancer Patient Treatment Outcome on HRQOL and Satisfaction with Cancer Care among Their Spouses

John T. Wei, Xihong Lin, R. Dunn, 2007 .

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

H M Sandler, John T. Wei, J. Wei, 2000, Urology.

Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.

D. Grignon, H. Sandler, Q. Zhang, 2013, International journal of radiation oncology, biology, physics.

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

D. Low, H. Sandler, M. Amin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

A. Zietman, H. Sandler, R. Uzzo, 2014, International journal of radiation oncology, biology, physics.

Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

H. Sandler, K. Bae, W. Shipley, 2015, Cancer.

Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

D. Grignon, H. Sandler, K. Bae, 2011, International journal of radiation oncology, biology, physics.

Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.

D. Grignon, H. Sandler, B. Donnelly, 2011, International journal of radiation oncology, biology, physics.

Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.

H. Sandler, R. Valicenti, J. Michalski, 2011, International journal of radiation oncology, biology, physics.

Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

H. Sandler, K. Bae, L. Souhami, 2010, International journal of radiation oncology, biology, physics.

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O

D. Grignon, H. Sandler, Chin-Lee Wu, 2005, International journal of radiation oncology, biology, physics.

Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy?

W. Curran, H. Sandler, W. Mckenna, 1992, International Journal of Radiation Oncology, Biology, Physics.

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.

P. Carroll, H. Sandler, M. Roach, 2020, JAMA oncology.

Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621

K. Badiozamani, D. Beyer, H. Sandler, 2017, Cancer.

Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer

R. Mehra, H. Sandler, R. Dess, 2017, Current Urology Reports.

Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy.

T. Daskivich, H. Sandler, Z. Zumsteg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men

Christopher U. Jones, A. Kishan, P. Boutros, 2021, JAMA network open.

Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy

D. Grignon, M. Hammond, H. Sandler, 2004, Clinical Cancer Research.

Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Benedick A Fraass, H. Sandler, S. Gebarski, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

L. Potters, K. Hoffman, A. Zietman, 2013, Journal of oncology practice.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Clinical experience using a video‐guided spirometry system for deep inhalation breath‐hold radiotherapy of left‐sided breast cancer

H. Sandler, B. Fraass, S. Shiao, 2015, Journal of applied clinical medical physics.

Imaging Changes after Stereotactic Radiosurgery of Primary and Secondary Malignant Brain Tumors

James M. Balter, James A. Hayman, D. Ross, 2004, Journal of Neuro-Oncology.

Aggressive papillary middle ear tumors: a report of two cases with review of the literature.

S. Telian, D. Ross, H. Sandler, 1994, Neurosurgery.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

A. Zietman, H. Sandler, J. Efstathiou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary visual outcomes after three-dimensional conformal radiation therapy for optic nerve sheath meningioma.

H. Sandler, J. Hayman, V. Elner, 2002, International journal of radiation oncology, biology, physics.

Current status of radiation therapy for bladder cancer

H. Sandler, A. Mirhadi, 2010, Expert review of anticancer therapy.

Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy

H. Sandler, W. Shipley, A. Althausen, 2005 .

Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.

H. Sandler, A. Thornton, H. Greenberg, 1991, Journal of neurosurgery.

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

T. Cascino, J. Buckner, H. Sandler, 2006, Journal of Neuro-Oncology.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors.

M. Martel, H. Sandler, W. Roa, 1997, International journal of radiation oncology, biology, physics.

The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma.

M. Martel, H. Sandler, R. Marsh, 1998, International journal of radiation oncology, biology, physics.

Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.

Christopher U. Jones, J. Torres-Roca, H. Sandler, 2015, International journal of radiation oncology, biology, physics.

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408

Christopher U. Jones, H. Sandler, A. Raben, 2017, Advances in radiation oncology.

Current role of radiation therapy for bladder cancer.

H. Sandler, A. Mirhadi, 2012, Seminars in oncology.

Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose.

J. Pouliot, I. Hsu, Adam Cunha, 2014, Practical radiation oncology.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly.

H. Sandler, A. Barkan, C. Jaffe, 1997, The Journal of clinical endocrinology and metabolism.

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.

Christopher U. Jones, R. Mak, H. Sandler, 2016, Urologic oncology.

Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.

D. Kuban, I. Kaplan, O. Garin, 2016, International journal of radiation oncology, biology, physics.

E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.

R. Shah, R. Mehra, H. Sandler, 2006, The Journal of urology.

Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.

D. Grignon, H. Sandler, M. Desilvio, 2007, International journal of radiation oncology, biology, physics.

Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer

H. Sandler, T. Pisansky, L. Kachnic, 2012, Supportive Care in Cancer.

Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

G. Gustafson, H. Sandler, M. Lock, 2022, International journal of radiation oncology, biology, physics.

Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.

John T. Wei, D. Kuban, I. Kaplan, 2013, International journal of radiation oncology, biology, physics.

H. Sandler, T. Pisansky, M. Desilvio, 2005, International journal of radiation oncology, biology, physics.

Treatment Choice and Quality of Care for Men With Localized Prostate Cancer

Benjamin A Spencer, Andrew K Stewart, Mark S Litwin, 2007, Medical care.

2222 Variation in the Definition of Clinical Target Volumes for Postoperative Conformal Radiation Therapy of

C. Catton, H. Sandler, M. Ritter, 2007 .

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

D. Grignon, H. Sandler, K. Bae, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late toxicity and biochemical recurrence after external‐beam radiotherapy combined with permanent‐source prostate brachytherapy

H. Sandler, M. Kuettel, M. Gillin, 2007, Cancer.

Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.

Patrick W McLaughlin, Lon Marsh, Theodore Lawrence, 2005, International journal of radiation oncology, biology, physics.

Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

Jan C Buckner, Bernd W Scheithauer, B. Scheithauer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

Christopher U. Jones, R. Hannan, H. Sandler, 2020 .

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

A. Markoe, H. Sandler, K. Bae, 2010, International journal of radiation oncology, biology, physics.

Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the α/β Ratio of Prostate Cancer

L. Kestin, H. Sandler, G. Duchesne, 2007 .

A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.

H. Sandler, M. Lock, J. Purdy, 2015 .

A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer.

H. Sandler, P. McLaughlin, V. Weinberg, 2003, International journal of radiation oncology, biology, physics.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

H. Sandler, R. Valicenti, M. Desilvio, 2006, International journal of radiation oncology, biology, physics.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH

M. Terris, M. Cooperberg, H. Sandler, 2017, The Prostate.

Unification of favourable intermediate‐, unfavourable intermediate‐, and very high‐risk stratification criteria for prostate cancer

M. Zelefsky, H. Sandler, D. Spratt, 2017, BJU international.

In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval.

R. Andridge, H. Sandler, C. Pan, 2008, International journal of radiation oncology, biology, physics.

Staging for prostate cancer

I. Thompson, H. Sandler, M. Roach, 2007, Cancer.

A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication

H. Sandler, S. Mathoulin-Pélissier, C. Bellera, 2018, Statistical methods in medical research.

Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer

Menggang Yu, H. Sandler, Menggang Yu, 2005 .

Individualized predictions of disease progression following radiation therapy for prostate cancer.

Menggang Yu, Jeremy M G Taylor, H. Sandler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone- a multi-institutional pooled analysis

D. Kuban, M. Zelefsky, A. Zietman, 2003 .

The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure.

Jeremy M G Taylor, H. Sandler, Howard Sandler, 2002, Biostatistics.

Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone

D. Kuban, M. Zelefsky, A. Zietman, 2006, Cancer.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Richard K Valicenti, Jeff M Michalski, Mack Roach, 2004, International journal of radiation oncology, biology, physics.

Randomized clinical trial of a family intervention for prostate cancer patients and their spouses

David C. Smith, K. Pienta, J. Montie, 2007, Cancer.

Living with prostate cancer: patients' and spouses' psychosocial status and quality of life.

David C. Smith, K. Pienta, J. Montie, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peter Chang, B. Reeve, H. Sandler, 2014, Journal of the National Cancer Institute.

JOINT LONGITUDINAL-SURVIVAL-CURE MODELS AND THEIR APPLICATION TO PROSTATE CANCER

Menggang Yu, H. Sandler, Menggang Yu, 2004 .

Combining Prostate-Specific Antigen Nadir and Time to Nadir Allows for Early Identification of Patients at Highest Risk for Development of Metastasis and Death Following Salvage Radiation Therapy

H. Sandler, W. Jackson, F. Feng, 2013 .

A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy

H. Sandler, W. Jackson, T. Morgan, 2013, Radiation oncology.

Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility.

K L Lam, J M Balter, R K Ten Haken, 1995, International journal of radiation oncology, biology, physics.

Tumor utilization committee

D. Grignon, M. Mehta, C. Willet, 2001 .

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, M. Lungren, 2022, npj Digital Medicine.

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.

A. Kishan, M. Sydes, D. Dearnaley, 2022, European urology.

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.

H. Sandler, E. Horwitz, T. Pisansky, 2019, International journal of radiation oncology, biology, physics.

Reporting of results in DART01/05 GICOR.

H. Sandler, T. Pisansky, M. Roach, 2015, The Lancet. Oncology.

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

Kyounghwa Bae, Alan Pollack, D. Grignon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

J. Galvin, H. Sandler, W. Bosch, 2013, International journal of radiation oncology, biology, physics.

Primary central-nervous-system lymphoma - treatment with multiagent systemic and intrathecal chemotherapy with radiation-therapy.

H. Sandler, L. Junck, H. Greenberg, 1993, International journal of oncology.

Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer.

H. Sandler, B. Fraass, R. Tuli, 2015, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.

M. Prados, T. Cascino, W. Curran, 1999, International journal of radiation oncology, biology, physics.

Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy.

H. Sandler, L. Junck, A. Thornton, 1997, American journal of clinical oncology.

Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP)

I. Kaplan, D. Beyer, H. Sandler, 2020, International Journal of Radiation Oncology*Biology*Physics.

Initial performance evaluation of an indirect-detection, active matrix flat-panel imager (AMFPI) prototype for megavoltage imaging.

J Yorkston, J H Siewerdsen, V. Scarpine, 1998, International journal of radiation oncology, biology, physics.

Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.

H. Sandler, F. Feng, D. Hamstra, 2011, International journal of radiation oncology, biology, physics.

A brain tumor dose escalation protocol based on effective dose equivalence to prior experience.

H. Sandler, R. T. Ten Haken, B. Fraass, 1998, International journal of radiation oncology, biology, physics.

Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment

John T. Wei, I. Kaplan, A. Kibel, 2017, The Journal of urology.

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Prediction of erectile function following treatment for prostate cancer.

John T. Wei, M. Cooperberg, P. Carroll, 2011, JAMA.

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy

K. Pienta, S. Jolly, K. Cooney, 2015, Advances in radiation oncology.

Use of quality indicators to evaluate the care of patients with localized prostate carcinoma

Martin G Sanda, Mark S Litwin, John T. Wei, 2003, Cancer.

Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.

Christopher U. Jones, A. Zietman, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms.

D L McShan, R K Ten Haken, B A Fraass, 1992, International journal of radiation oncology, biology, physics.

Long-term Androgen Deprivation Therapy Improves Metastasis Free and Cause-specific Survival Even in the Setting of Dose Escalated Radiation for Localized Prostate Cancer

H. Sandler, F. Feng, D. Hamstra, 2010 .

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

H. Sandler, K. Bae, J. Efstathiou, 2008, European urology.

Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.

John T. Wei, David C. Miller, R. Dunn, 2006, Urology.

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

A. Zietman, H. Sandler, R. Uzzo, 2013, The Lancet. Oncology.

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

A. Zietman, H. Sandler, W. Shipley, 2009, Urology.

Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer

T. Daskivich, M. Luu, H. Sandler, 2021, The Journal of urology.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

A. Kishan, L. Collette, P. Boutros, 2019, European Urology.

Anatomical patterns of recurrence following biochemical relapse after post‐prostatectomy salvage radiation therapy: a multi‐institutional study

David C. Miller, R. Hannan, M. Folkert, 2017, BJU international.

Treatment of T3a bladder cancer with iridium implantation.

H. Sandler, C. Perez-Tamayo, H. B. Grossman, 1993, Urology.

Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial

A. Zietman, H. Sandler, J. Efstathiou, 2017 .

Salvage radiotherapy in the treatment of prostate cancer.

H. Sandler, C. Tsien, 2003, Urology.

Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up

S. Tomlins, R. Mehra, H. Sandler, 2016, Prostate Cancer and Prostatic Diseases.

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

D. Grignon, Min Zhang, H. Sandler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

A. Markoe, H. Sandler, J. Purdy, 2004, International journal of radiation oncology, biology, physics.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

D. Kuban, M. Zelefsky, A. Zietman, 2004, International journal of radiation oncology, biology, physics.

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.

John T. Wei, T. Skolarus, D. Kuban, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx).

D. Beyer, H. Sandler, É. Vigneault, 2021, International journal of radiation oncology, biology, physics.

What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?

H. Sandler, P. McLaughlin, V. Weinberg, 2003, Urology.

Comprehensive Comparison of Heal th-Related Qual i ty of Li fe Af ter Contemporary Therapies for Local ized Prostate Cancer

John T. Wei, R. Dunn, J. Montie, 2001 .

Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.

John T. Wei, D. Kuban, R. Dunn, 2013, Urology.

Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy.

H. Sandler, 2004, The Journal of urology.

Is prostate cancer like lung cancer?

H. Sandler, 2004, International journal of radiation oncology, biology, physics.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline

K. Hoffman, H. Sandler, J. Efstathiou, 2019, The Journal of urology.

Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02

H. Sandler, M. Ritter, W. Shipley, 2007, Clinical Cancer Research.

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

T. McDonnell, M. Hammond, H. Sandler, 2006, International journal of radiation oncology, biology, physics.

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

H. Sandler, R. Dess, R. Valicenti, 2022, Cancer.

Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA ≤ 20: Initial Results of RTOG 94-08

Christopher U. Jones, H. Sandler, M. Amin, 2010 .

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.

A. Markoe, H. Sandler, J. Purdy, 2003, International journal of radiation oncology, biology, physics.

Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.

A. Markoe, H. Sandler, J. Purdy, 2002, Seminars in radiation oncology.

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).

D. Grignon, H. Sandler, T. Pisansky, 2007, International journal of radiation oncology, biology, physics.

Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy.

R. Dunn, H. Sandler, M. Sanda, 2006, Urology.

A single plan approach for differentially dosing sequential target volumes.

R K Ten Haken, L H Marsh, H M Sandler, 1997, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

I. Kaplan, D. Beyer, H. Sandler, 2018, International journal of radiation oncology, biology, physics.

Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models

Yongseok Park, Donna P Ankerst, Tom Pickles, 2013, Biometrics.

The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.

P. Carroll, H. Sandler, Irwin H. Lee, 2008, The Journal of urology.

Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.

D. Grignon, H. Sandler, B. Donnelly, 2010, International journal of radiation oncology, biology, physics.

Prostate Intrafraction Translation Margins for Real-Time Monitoring and Correction Strategies

T. Solberg, J. Balter, H. Sandler, 2011, Prostate cancer.

Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy.

K. Griffith, H. Sandler, P. McLaughlin, 2001, International journal of radiation oncology, biology, physics.

Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.

H. Sandler, J. Efstathiou, W. Shipley, 2013, The oncologist.

A Tissue Biomarker–Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02

R. Stoyanova, H. Sandler, K. Bae, 2014, Clinical Cancer Research.

The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02

M. Hammond, H. Sandler, K. Bae, 2009, Clinical Cancer Research.

Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.

D. Grignon, H. Sandler, K. Bae, 2008, International journal of radiation oncology, biology, physics.

Variations in quality of care for men with early-stage prostate cancer.

John T. Wei, David C. Miller, R. Dunn, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of low‐dose‐rate brachytherapy and androgen‐deprivation therapy decreases biochemical failure and prostate cancer death compared with dose‐escalated external‐beam radiation therapy for high‐risk prostate cancer

G. Merrick, H. Sandler, P. McLaughlin, 2013, Cancer.

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

D. Kuban, M. Zelefsky, A. Zietman, 2006, International Journal of Radiation Oncology, Biology, Physics.

Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2015, International journal of radiation oncology, biology, physics.

The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy.

Scott Hadley, Daniel A Hamstra, Karen Vineberg, 2013, International journal of radiation oncology, biology, physics.

Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.

D. Grignon, B. Fisher, H. Sandler, 2007, International journal of radiation oncology, biology, physics.

Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate.

H. Sandler, P. McLaughlin, M. Roach, 2003, Urology.

Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05).

D. Grignon, H. Sandler, T. Pisansky, 2009, International journal of radiation oncology, biology, physics.

A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

D. Kuban, C. Roehrborn, P. Scardino, 2005, Urology.

Personalized Medicine and Imaging A Tissue Biomarker – Based Model That Identi fi es Patients with a High Risk of Distant Metastasis and Differential Survival by Length of AndrogenDeprivation Therapy in RTOG Protocol 92-02

R. Stoyanova, H. Sandler, K. Bae, 2014 .

Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy.

H. Sandler, P. McLaughlin, C. Pan, 2002, International journal of radiation oncology, biology, physics.

Family history of prostate cancer and relapse after definitive external beam radiation therapy.

K. Cooney, R. Dunn, H. Sandler, 2003, International journal of radiation oncology, biology, physics.

Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy

A. Zietman, H. Sandler, R. Uzzo, 2010 .

Reply to K. Lin et al

H. Sandler, K. Bae, L. Souhami, 2010 .

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

D. Yan, H. Sandler, M. Lock, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

H. Sandler, P. Tran, A. Mitani, 2023, Research square.

Local failure in high grade prostate cancer: the importance of local and systemic therapy

A. Kishan, H. Sandler, 2020, Translational andrology and urology.

Long-term results of NRG Oncology/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate.

I. Hsu, G. Gustafson, H. Sandler, 2019, International journal of radiation oncology, biology, physics.

Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Cécile Proust-Lima, Kyounghwa Bae, Donna P Ankerst, 2008, International journal of radiation oncology, biology, physics.

Determinants of change of prostate-specific antigen over time and its association with recurrence following external beam radiation therapy of prostate cancer in 5 large cohorts

Cécile Proust-Lima, J. M. Taylor, D. Ankerst, 2010 .

Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy.

H. Sandler, R. T. Ten Haken, A. Lichter, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The treatment planning of segmental, conformal stereotactic radiosurgery utilizing a standard multileaf collimator.

J M Balter, H M Sandler, P G Archer, 1999, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

D. Brachman, C. Catton, H. Sandler, 2018, International Journal of Radiation Oncology*Biology*Physics.

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

John T. Wei, D. Kuban, R. Dunn, 2017, International journal of radiation oncology, biology, physics.

A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.

H. Sandler, M. Kuettel, M. Desilvio, 2006, International journal of radiation oncology, biology, physics.

Stereotactic radiosurgery of cerebral arteriovenous malformations with a multileaf collimator and a single isocenter.

D. Ross, J. Balter, H. Sandler, 2000, Neurosurgery.

A customized non-axial external beam technique for treatment of prostate carcinomas.

H. Sandler, R. T. Ten Haken, L. Marsh, 1992, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Measurement of prostate motion over the course of radiotherapy

K. Lam, J. Balter, H. Sandler, 1993 .

Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement.

Ronald C. Chen, H. Sandler, S. Freedland, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring dose-intensity: carefully comparing high-dose with low-dose external-beam radiotherapy for prostate cancer.

H. Sandler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

I. Hsu, H. Sandler, P. McLaughlin, 2010, International journal of radiation oncology, biology, physics.

Interval to biochemical failure as a biomarker for cause‐specific and overall survival after dose‐escalated external beam radiation therapy for prostate cancer

H. Sandler, F. Feng, D. Hamstra, 2012, Cancer.

RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

H. Sandler, J. Purdy, R. Valicenti, 2003, International journal of radiation oncology, biology, physics.

Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.

John T. Wei, R. Dunn, H. Sandler, 2004, Urology.

Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.

Martin G Sanda, R. Dunn, H. Sandler, 2010, Urology.

Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)

H. Sandler, M. Lock, J. Purdy, 2014 .

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Christopher U. Jones, R. Hannan, H. Sandler, 2023, European urology.

Protein Kinase A RI-alpha (PKA) Predicts Prostate Cancer Outcome: An Analysis of Radiation Therapy Oncology Group Trial 86-10

D. Grignon, H. Sandler, K. Bae, 2009 .

Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants.

P L Roberson, P. Roberson, H. Sandler, 1997, International journal of radiation oncology, biology, physics.

Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.

D. Kuban, M. Zelefsky, C. Catton, 2005, International journal of radiation oncology, biology, physics.

Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer

I. Kaplan, D. Beyer, H. Sandler, 2016 .

A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.

H. Sandler, J. Michalski, S. Rosenthal, 2010 .

Side effects of radiation therapy.

H. Sandler, 1991, American family physician.

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.

H. Sandler, W. Jackson, F. Feng, 2016, European urology.

Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life.

H. Sandler, C. Yashar, G. Bajaj, 2022, International journal of radiation oncology, biology, physics.

Megavoltage imaging with a large-area, flat-panel, amorphous silicon imager.

J Yorkston, J H Siewerdsen, H. Sandler, 1996, International journal of radiation oncology, biology, physics.

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

H. Sandler, K. Bae, W. Shipley, 2009, Journal of the National Cancer Institute.

Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking.

Jean Pouliot, Patrick A Kupelian, James M Balter, 2007, International journal of radiation oncology, biology, physics.

Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer

A. Zietman, H. Sandler, B. Yeap, 2013, Cancer.

CLINICAL EXPERIENCE WITH A FULLY THREE-DIMENSIONAL TREATMENT PLANNING SYSTEM

Howard M. Sandler, Allen S. Lichter, Allan F. Thornton, 1992 .

Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, M. Lock, 2021, International journal of radiation oncology, biology, physics.

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable

T. Daskivich, M. Luu, H. Sandler, 2020, JAMA network open.

Prostate-specific antigen following prostate radiotherapy: how low can you go?

M. Jiroutek, H. Sandler, P. McLaughlin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer

John T. Wei, R. Dunn, H. Sandler, 2004 .

Preliminary Analysis of 3D-CRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Toxicity Report

J. Galvin, H. Sandler, J. Michalski, 2011 .

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.

M. Michaelson, A. Zietman, H. Sandler, 2023, European urology oncology.

Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.

H. Sandler, M. Kuettel, J. Crook, 2010, International journal of radiation oncology, biology, physics.

Daily prostate targeting using implanted radiopaque markers.

Randall K Ten Haken, James M Balter, Daniel L McShan, 2001, International journal of radiation oncology, biology, physics.

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.

D. Beyer, C. Catton, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer

H. Sandler, M. Regan, M. Sanda, 2014, Cancer.

Localization of the prostatic apex for radiotherapy using implantable markers

H. Sandler, P. McLaughlin, A. Lichter, 1992 .

Novel 4D-MRI of tumor infiltrating vasculature: characterizing tumor and vessel volume motion for selective boost volume definition in pancreatic radiotherapy

H. Sandler, Debiao Li, B. Fraass, 2018, Radiation oncology.

Low grade gliomas: preliminary analysis of failure patterns among patients treated using 3D conformal external beam irradiation.

D. Ross, H. Sandler, L. Junck, 1995, International journal of radiation oncology, biology, physics.

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

J. Deasy, D. Low, H. Sandler, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

D. Grignon, A. Zietman, H. Sandler, 2016 .

Satisfaction with information used to choose prostate cancer treatment.

John T. Wei, R. Dunn, E. Klein, 2014, The Journal of urology.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

K. Hoffman, H. Sandler, J. Efstathiou, 2018, The Journal of urology.

Radiation for prostate cancer: intensity modulated radiation therapy versus proton beam.

H. Sandler, B. Hoppe, C. Bryant, 2015, Journal of Urology.

Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828.

H. Sandler, B. Movsas, W. Lee, 2014, Practical radiation oncology.

Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.

Martin G Sanda, James Montie, K. Griffith, 2003, Urology.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

D. Kuban, M. Kattan, C. Roehrborn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation Therapy Oncology Group (RTOG) 9408: A Secondary Analysis of the Risk of Death From Second Cancers Comparing Whole Pelvic (WP) Radiation Therapy (RT) to Prostate Only (PO) RT and Neoadjuvant Hormonal Therapy (NHT) + RT to RT Alone

Christopher U. Jones, H. Sandler, M. Roach, 2013 .

Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Experience With Three-Dimensional Treatment Planning.

Sandler, H. Sandler, D. McShan, 1992, Seminars in Radiation Oncology.

Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution.

H. Sandler, D. McShan, A. Lichter, 1992, International journal of radiation oncology, biology, physics.

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415

H. Sandler, E. Horwitz, F. Feng, 2021, PloS one.

A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy

D. Kuban, M. Zelefsky, C. Catton, 2004 .

Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.

A. D'Amico, P. Kantoff, P. Carroll, 2007, The Journal of urology.

Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model

Menggang Yu, H. Sandler, Menggang Yu, 2008 .

Analysis of localization errors in the definition of the mantle field using a beam's eye view treatment-planning system.

H. Sandler, A. Eisbruch, A. Turrisi, 1996, International journal of radiation oncology, biology, physics.

A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy

D. Kuban, M. Zelefsky, C. Catton, 2004 .

Clinical Experience with the Calypso® 4D Localization System in Prostate Cancer Patients: Implantation, Tolerance, Migration, Localization and Real Time Tracking

Sanford L. Meeks, Dale W. Litzenberg, Patrick A. Kupelian, 2005 .

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial

G. Gustafson, D. Yan, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols.

K. Lam, J. Balter, H. Sandler, 2005, International journal of radiation oncology, biology, physics.

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

D. Kuban, S. Hancock, A. Zietman, 1999, JAMA.

Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

C. Ménard, A. Zietman, C. Catton, 2010, International journal of radiation oncology, biology, physics.

Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy

H. Sandler, D. Hamstra, C. Pan, 2012, Radiation oncology.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

H. Sandler, K. Bae, J. Efstathiou, 2008, European urology.

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

M. Rubin, A. Chinnaiyan, B. Delahunt, 2014, Archives of pathology & laboratory medicine.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

M. Cooperberg, H. Sandler, P. Tran, 2018, European urology.

Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.

H. Sandler, F. Feng, D. Hamstra, 2013, International journal of radiation oncology, biology, physics.

Prediction of erectile function following treatment for prostate cancer.

John T. Wei, M. Cooperberg, P. Carroll, 2011, JAMA.

Five-year patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.

I. Kaplan, H. Sandler, E. Horwitz, 2022, International journal of radiation oncology, biology, physics.

A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

D. Kuban, C. Roehrborn, P. Scardino, 2008, Urology.

The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure.

H. Sandler, Jeremy M. G. Taylor, Ngayee Law, 2002, Biostatistics.

Non-local means denoising of SG-KS-4D-MRI using block matching 3D: Implications for pancreatic tumor registration and segmentation

H. Sandler, Debiao Li, J. Pang, 2016 .

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.

L. Kestin, H. Sandler, T. Pickles, 2011, International Journal of Radiation Oncology, Biology, Physics.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Summary.

H. Sandler, R. Rumble, Scott C. Morgan, 2019, Journal of oncology practice.

Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial.

H. Sandler, P. Tran, É. Vigneault, 2023, International journal of radiation oncology, biology, physics.

11 3D conformal radiotherapy for malignant astrocytomas: Dose escalation to 90 Gy

H. Sandler, L. Junck, E. Radany, 1997 .

I. Hsu, H. Sandler, V. Weinberg, 2010, International journal of radiation oncology, biology, physics.

Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

D. Kuban, M. Kattan, C. Roehrborn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer

H. Sandler, M. Regan, M. Sanda, 2014, Cancer.

Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, D. Citrin, 2021, International journal of radiation oncology, biology, physics.

Radiosensitization with Carotid Arterial Infusion of Bromodeoxyuridine (BUdR) ± 5 Fluorouracil (5FU) Biomodulation with Focal External Beam Radiation (FEBT) for Malignant Gliomas

H. Sandler, S. Gebarski, L. Junck, 1991 .

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Christopher U. Jones, K. Pienta, H. Sandler, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

High-risk prostate cancer: how high is high?

H. Sandler, 2002, Cancer journal.